
Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Follow FastWave's Journey
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.